{
    "clinical_study": {
        "@rank": "121061", 
        "arm_group": [
            {
                "arm_group_label": "Ertugliflozin (5 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Once daily for a 26-week placebo-controlled treatment period of Phase A and for a 26-week active-controlled treatment period (Phase B). In Phase B, participants not rescued with open label metformin in Phase A, will also receive placebo to metformin. Participants rescued with metformin in Phase A will enter into Phase B and continue to receive open-label metformin in addition to their original randomized treatment."
            }, 
            {
                "arm_group_label": "Ertugliflozin (15 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Once daily for a 26-week placebo-controlled treatment period of Phase A and for a 26-week active-controlled treatment period (Phase B). In Phase B, participants not rescued with open label metformin in Phase A, will also receive placebo to metformin. Participants rescued with metformin in Phase A will enter into Phase B and continue to receive open-label metformin in addition to their original randomized treatment."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Once daily for a 26-week placebo-controlled treatment period of Phase A. In Phase B, participants not rescued with open-labeled metformin in Phase A will also receive blinded metformin in addition to placebo. Participants rescued with metformin in Phase A will enter into Phase B and continue to receive open-label metformin in addition to their original randomized treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "This trial will evaluate the efficacy and safety of ertugliflozin monotherapy in the\n      treatment of subjects with type 2 diabetes mellitus (T2DM) and inadequate glycemic control\n      on diet and exercise.  This trial consists of a run-in period of 3 to 11 weeks, a 26-week\n      placebo-controlled treatment period (Phase A), and a 26-week active treatment period (Phase\n      B).  The primary hypothesis of the trial is that at Week 26, the mean reduction from\n      baseline in hemoglobin A1c (HbA1c) for 15 mg ertugliflozin is greater than that for placebo."
        }, 
        "brief_title": "A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003)", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of T2DM in accordance to American Diabetes Association guidelines\n\n          -  Participants with no prior allowable oral anti-hyperglycemic agents (AHA) for at\n             least 8 weeks prior to study participation or participants on a single allowable oral\n             AHA at the start of study participation\n\n          -  Particpants on a single allowable AHA must be willing to discontinue this medication\n             at the Screening Visit (S2) and remain off this medication for the duration of the\n             trial.  Allowable oral AHAs for discontinuation are metformin, sulfonylureas,\n             dipeptidyl peptidase-4 (DPP-4) inhibitors, glinides or alpha-glucosidase inhibitors.\n\n        Exclusion Criteria:\n\n          -  History of myocardial infarction, unstable angina, arterial revascularization,\n             stroke, transient ischemic attack, or New York Heart Association (NYHA) functional\n             class III-IV heart failure within 3 months of study participation\n\n          -  A clinically significant electrocardiogram abnormality\n\n          -  A history of malignancy \u22645 years prior to study participation, except for adequately\n             treated basal or squamous cell skin cancer or in situ cervical cancer\n\n          -  A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2\n             (SGLT2) inhibitor or metformin\n\n          -  On a blood pressure or lipid altering medication that have not been on a stable dose\n             for at least 4 weeks prior to study participation\n\n          -  A surgical procedure within 4 weeks prior to study participation or planned major\n             surgery during the trial\n\n          -  Donation of blood or blood products within 6 weeks of study participation or plans to\n             donate blood or blood products at any time during the trial\n\n          -  Pregnant or breast-feeding, or is expecting to conceive during the trial, including\n             14 days following the last dose of study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01958671", 
            "org_study_id": "8835-003", 
            "secondary_id": [
                "2013-002519-90", 
                "B1521022"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Ertugliflozin (5 mg)", 
                    "Ertugliflozin (15 mg)"
                ], 
                "description": "One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).", 
                "intervention_name": "Ertugliflozin (5 mg)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "MK-8835", 
                    "PF-04971729"
                ]
            }, 
            {
                "arm_group_label": "Ertugliflozin (15 mg)", 
                "description": "One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).", 
                "intervention_name": "Ertugliflozin (10 mg)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "MK-8835", 
                    "PF-04971729"
                ]
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin (5 mg)", 
                    "Placebo"
                ], 
                "description": "One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).", 
                "intervention_name": "Placebo to Ertuglifozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening ) for 2 weeks and 1000 mg (2 tablets 500 mg ) in the morning and 1000 mg (2 tablets 500 mg) in the evening thereafter.", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin (5 mg)", 
                    "Ertugliflozin (15 mg)"
                ], 
                "description": "Placebo matching metformin.", 
                "intervention_name": "Placebo to Metformin", 
                "intervention_type": "Drug", 
                "other_name": "Glucophage XR, Carbophage SR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, Diaformin, Siofor and Metfogamma."
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85018"
                    }, 
                    "name": "Call for Information (Investigational Site 1086)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90022"
                    }, 
                    "name": "Call for Information (Investigational Site 1082)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hallandale Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33009"
                    }, 
                    "name": "Call for Information (Investigational Site 1043)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Margate", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33063"
                    }, 
                    "name": "Call for Information (Investigational Site 1087)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33015"
                    }, 
                    "name": "Call for Information (Investigational Site 1090)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32804"
                    }, 
                    "name": "Call for Information (Investigational Site 1079)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ormond Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32174"
                    }, 
                    "name": "Call for Information (Investigational Site 1042)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockbridge", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30281"
                    }, 
                    "name": "Call for Information (Investigational Site 1088)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Metairie", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70006"
                    }, 
                    "name": "Call for Information (Investigational Site 1084)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lenoir", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28645"
                    }, 
                    "name": "Call for Information (Investigational Site 1041)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marion", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43302"
                    }, 
                    "name": "Call for Information (Investigational Site 1035)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "Call for Information (Investigational Site 1091)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kingsport", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37660"
                    }, 
                    "name": "Call for Information (Investigational Site 1096)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77004"
                    }, 
                    "name": "Call for Information (Investigational Site 1089)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77036"
                    }, 
                    "name": "Call for Information (Investigational Site 1085)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Schertz", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78154"
                    }, 
                    "name": "Call for Information (Investigational Site 1078)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Henrico", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23233"
                    }, 
                    "name": "Call for Information (Investigational Site 1083)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Walla Walla", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "99362"
                    }, 
                    "name": "Call for Information (Investigational Site 1037)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Medical Information Centre / Centre de l'information medicale de Merck Canada", 
                    "phone": "514-428-8600 / 1-800-567-2594"
                }, 
                "facility": {
                    "address": {
                        "city": "Kirkland", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H9H 3L1"
                    }, 
                    "name": "Merck Canada"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Patrizia Nardini", 
                    "phone": "39 06 361911"
                }, 
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy"
                    }, 
                    "name": "MSD Italia S.r.l."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Italy"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 3, Randomized, Double-blind, Placebo-controlled, 26-week Multicenter Study With a 26-Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from Baseline In Hemoglobin A1c (HbA1c) at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Number of Participants Experiencing An Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 52"
            }, 
            {
                "measure": "Number of Participants Discontinuing Study Treatment Due to an AE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 52"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01958671"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Fasting Plasma Glucose (FPG) at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Change from Baseline in Body Weight at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Number of Participants with a HbA1c <7% (53 mmol/mol) at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Week 26"
            }, 
            {
                "measure": "Change from Baseline in 2-hour Post-prandial Plasma Glucose at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Change from Baseline in Systolic Blood Pressure at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Change from Baseline in Diastolic Blood Pressure at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}